Company* (Country; Symbol) | Company* | Product |
Terms/Details (Date) |
| | |||
Affymetrix Inc. (AFFX) |
Axon Instruments Inc. (ASX:AXN) |
Axon got rights covering the manufacture and sale of scanners and software for conventional spotted microarrays |
The deal inlcudes an option for an extension to cover diagnostic applications; it does not involve Affymetrix's GeneChip technology (4/12) |
Avid Bioservices Inc. (subsidiary of Peregrine Pharmaceuticals Inc.; PPHM) |
Halozyme Therapeutics Inc. (OTC BB:HZYM) |
Avid will manufacture Halozyme's first recombinant human enzyme |
The enzyme will be used in the development of products designed to offer synthetic alternatives to enzymes used in the infertility and ophthalmology markets (4/12) |
Cell Analysis* |
Impath Inc. (OTC BB:IMPHQ) |
Cell Analysis' Quantitative Cellular Assessment system, which analyzes tumor cells |
Impath will provide the system exclusively to its clients, with launch expected in 2Q:04; terms were not disclosed (3/16) |
Cell Signaling Technology Inc.* |
Zeptosens AG* (Switzerland) |
Deal for the use and resale of certain CST reagents by Zeptosens in conjunction with its protein microarray platform |
The reagents will be used with Zeptosens' ZeptoMARK CeLyA product; terms were not disclosed (4/19) |
Cell Signaling Technology Inc.* |
ProQinase GmbH* (Germany) |
CST will distribute the full line of ProQinase's purified enzymes |
Combining the enzymes with CST's phos pho-specific antibody reagents is expected to create value in kinase discovery; terms were not disclosed (3/29) |
Cobra Biomanufacturing plc (UK;LSE:CBF) |
Oncolytics Biotech Inc. (Canada;ONCY) |
Cobra will manufacture and supply Reolysin for Phase I and II trials |
The product is based on Oncolytics' formulation of the human reovirus; terms were not disclosed (4/5) |
Cobra Biomanufacturing plc (UK; LSE:CBF) |
Avidex Ltd.* (UK) |
Cobra will manufacture Avidex's lead cancer drug through Phase I trials |
The product is based on soluble monoclonal T-cell receptor technology; terms were not disclosed (3/9) |
Epitomics Inc.* |
Strategic Diagnostics Inc. (SDIX) |
Joint marketing and services agreement under which SDI will refer third parties to Epitomics for rabbit hybridoma services |
As part of the deal SDI will provide custom polyclonal service for rabbit hybridoma development to Epitomics; terms were not disclosed (3/17) |
Exiqon A/S* (Denmark) Genomics Trilogy platform |
U.S. Genomics Inc.* |
Worldwide license agreement to incorporate Exiqon's Locked Nucleic Acid chemistries into reagent kits for the U.S. |
Reagents incorporating the technology are expected to be introduced in the third quarter; terms of the deal were not disclosed (4/14) |
Third Wave Technologies Inc. (TWTI) |
Innogenetics NV (Belgium; Euronext:INNX) |
Innogenetics will distribute Invader molecular diagnostic products in Europe in the field of genetic testing |
Innogenetics will make minimum payments to Third Wave during the deal's four-year term (4/27) |
Transgenomic Inc. (TBIO) |
Regado Biosciences* |
Transgenomic will manufacture the two components of an antidote-controlled, regulatable anticoagulant therapy |
Transgenomic also will provide related services in support of Regado's advancement toward an IND filing (3/22) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
